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Kjaersgaard G, Madsen K, Marcussen N, Christensen S, Walter
S, Jensen BL. Tissue injury after lithium treatment in human and rat
postnatal kidney involves glycogen synthase kinase-3-positive epi-
thelium. Am J Physiol Renal Physiol 302: F455–F465, 2012. First
published November 16, 2011; doi:10.1152/ajprenal.00144.2011.—It was
hypothesized that lithium causes accelerated and permanent injury to
the postnatally developing kidney through entry into epithelial cells of
the distal nephron and inhibition of glycogen synthase kinase-3
(GSK-3). GSK-3 immunoreactivity was associated with glomeruli,
the thick ascending limb of Henle’s loop, and collecting ducts in the
developing and adult human and rat kidney. In rats, the abundance of
inactive, phosphorylated GSK-3 (pGSK-3) protein decreased dur-
ing postnatal development. After feeding of dams with litters lithium
[50 mmol Li/kg chow, postnatal (P) days 7–28], the offspring showed
plasma lithium concentration of 1.0 mmol/l. Kidneys from lithium-
treated rat pups exhibited dilated distal nephron segments with mi-
crocysts. Stereological analysis showed reduced cortex and outer
medullary volumes. Lithium increased pGSK-3 and the proliferation
marker proliferating cell nuclear antigen (PCNA) protein abundances
in the cortex and medulla. After lithium treatment, pGSK-3-
immunopositive cells exhibited restricted distribution and were asso-
ciated primarily with subsets of cells in dilated and microcystic
segments of cortical collecting ducts. After 6 wk of lithium discon-
tinuation, adult rats exhibited attenuated urine concentration capacity
and diminished outer medullary volume. Histological sections of two
nephrectomy samples and a biopsy from three long-term lithium-
treated patients showed multiple cortical microcysts that originated
from normally appearing tubules. Microcysts were lined by a cuboidal
PCNA-, GSK-3-, and pGSK-3-immunopositive epithelium. The
postnatal rat kidney may serve as an experimental model for the study
of lithium-induced human kidney injury. The data are compatible with
a causal relationship between epithelial entry of lithium into cells of
the aldosterone-sensitive distal nephron, inactivation of GSK-3,
proliferation, and microcysts.
development; cyst; proliferation; medulla, collecting duct
LITHIUM IS USED FOR PROPHYLAXIS and treatment of affective
disorders and is often given for years, but its use is associated with
a range of renal functional and structural adverse effects (3). In a
pioneering study from 1982, lithium precipitated tissue injury,
decreased the glomerular filtration rate (GFR), and urine concen-
trating ability when administered from birth through 8 postnatal
weeks, while it had no effect on the prenatal kidney (28). Lithium
discontinuation did not resolve functional or structural injury (10,
28). In contrast, long-term lithium treatment of the adult rat kidney
led to reversible lowering of concentrating ability, intact GFR, and
slight morphological alteration in the distal tubule and collecting
duct (8). The postnatal developing kidney therefore appears to be
an attractive model for the study of tissue injury that typically
develops with chronic use in human patients (microcysts, tubular
dilatations). The reason for this differential sensitivity to lithium
has not been elucidated. The rodent kidney has 50% of
nephrons at birth and no inner medulla (4). Formation of new
nephrons continues until postnatal (P) days 7–9 (23). The medulla
expands in the second and third postnatal weeks by cell prolifer-
ation and apoptotic remodeling in the loop of Henle and collecting
ducts with a concomitant surge in urine concentrating ability (30).
The suckling phase is characterized by a paucity of sodium supply
because of a low NaCl content in milk (11). Lithium is reabsorbed
passively along the proximal tubule (25, 40) and reabsorbed in the
distal nephron only during conditions of sodium depletion in rats
(39). In the present study, we hypothesized that postnatal lithium-
induced kidney injury is associated with the narrow developmen-
tal “window” around weaning with avid sodium retention, so-
matic growth, and medullary proliferation. A recognized target for
lithium in the kidney that may be relevant to an understanding of
epithelial injury is glycogen synthase kinase-3 (GSK-3).
GSK-3 promotes apoptosis, inhibits proliferation, and is ex-
pressed in the adult kidney (5, 17, 29). Lithium inhibits GSK-3
activity by phosphorylation of the serine 9 residue pGSK-3-s9
(35). Cellular localization and developmental regulation of
GSK-3 and pGSK-3 in immature rodent and human kidney are
not clear. We hypothesized an inverse relationship between renal
GSK-3 activity and postnatal kidney development in such a way
that proliferation is favored in very early stages and higher
abundance or activity of GSK-3 supports the antiproliferative
state that prevails in the mature kidney. We hypothesized that
lithium entry in distal nephron segments inhibits GSK-3 and
disrupts the balance between proliferative and apoptotic signals.
The hypotheses were tested in a rat model given lithium in a
restricted postnatal developmental window (P7–P28) followed by
analysis of kidney tissue by unbiased quantitative stereology,
immunohistochemistry, Western blotting, and functional tests of
urine concentrating ability. Localization of GSK-3 was investi-
gated in fetal and adult human kidney tissue and, uniquely, in
kidney tissue from three long-term lithium-treated patients.
MATERIALS AND METHODS
Animal Experiments
Animals were housed at the Biomedical Laboratory, University of
Southern Denmark. All procedures conformed to the Danish national
guidelines for the care and handling of animals and to the published
guidelines from the National Institutes of Health. Female Sprague-
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Dawley and Wistar rats were used for breeding. Dams and pups were
kept on a 12:12-h light-dark cycle and had free access to standard
pathogen-free rat chow (Na 2 g/kg, Cl 5 g/kg; catalog no. 1310,
Altromin, Lage, Germany) and tap water.
Series 1. Litters were reduced to 10 pups within 24 h after birth to
ensure equal feeding. At P0, 7, 14, 21, and 28, rat pups were
euthanized by decapitation. The kidney cortex and medulla were
separated using a stereomicroscope and snap frozen in liquid nitrogen.
A group of animals was anesthetized by intraperitoneal (ip) injections
of pentobarbital sodium (50 mg/kg), and kidneys were fixed by
perfusion through the left cardiac ventricle with 4% phosphate buff-
ered formaldehyde.
Series 2. Litters were reduced to 8 pups (4 males, 4 females) within
24 h after birth. From P7 to P28, dams were fed either lithium-
enriched (50 mmol Li/kg diet) or standard rat chow. Lithium was
administered as lithium citrate. Animals had free access to tap water,
isotonic saline (Pharmacy, Odense University Hospital), and a solid
salt lick (100% NaCl, Dyrenes Supermarked, Odense, Denmark). At
P29, rats were anesthetized by ip injections of pentobarbital sodium
(50 mg/kg). Blood was collected by cardiac puncture, and plasma was
isolated by centrifugation. Kidneys were separated into cortex and
medulla as described above and snap frozen in liquid nitrogen. A
group of animals was fixed by systemic perfusion as described above.
Series 3. Dams were treated with either lithium-enriched or stan-
dard rat chow as described above from P7. Treatment was terminated
at P28, and rats continued to be fed a standard diet. At P68, animals
were placed in metabolic cages and after a 2-day run in period, urine
was collected for baseline measurements for 2 consecutive days. Rats
were then water deprived for 30 h. Urine was collected at 12 h of water
deprivation and discarded and at 24 h. Then, rats were given an ip
injection of dDAVP (1 g/kg), and urine collection continued for 6 h,
to a total of 30 h. A bolus injection of dDAVP was applied to ensure
animals reached their maximal urinary concentration level. Animals
were anesthetized as described above, and blood was collected by
heart puncture. From each animal, the inner medulla was collected
from one kidney while the other kidney was divided into cortex and
medulla and snap frozen. A group of animals was fixed by systemic
perfusion as described above.
Human Kidney Tissue
Tissue samples from patients undergoing nephrectomy due to
cancer were collected. The samples were taken from tissue not
affected by the tumor and used as controls. All patients gave informed
written consent to participate, and experiments were approved by the
Regional Biomedical Research Ethics Committee (S-VF-20010035).
Kidney tissue was fixed in 4% formaldehyde for 24 h and embedded
in paraffin. The samples from human fetal kidneys and human kidneys
from patients treated with lithium were obtained from the archive
at the Department Clinical Pathology, Odense University, and from
the Department of Clinical Medicine, Aarhus University, as ap-
proved by the Regional Biomedical Research Ethics Committee
(S-VF-20090148). Human lithium-treated kidney samples were the
following.
Case 1. Male, age 71, diagnosed with bipolar disorder and treated
with lithium for 28 yr (kidney from nephrectomy). The patient
suffered from thirst, polydipsia, and frequent voiding. Pathological
description mentions “multicystic kidney (lithium-induced) with renal
cell carcinoma.”
Table 1. Effect of lithium treatment on basal
parameters at P28
Control (n  8) Lithium (n  18)
Body weight, g 82.9  1.6 63.5  2.9*
Total kidney weight, mg 914.3  32.0 784.4  61.9
Kidney weight/body weight ratio, mg/g 11.0  0.2 12.1  0.5
Plasma osmolality, mosmol/kgH2O 287.1  1.2 287.8  0.8
Plasma [Na], mM 131.0  0.7 128.2  0.9
Plasma [Li], mM 0.03  0.002 0.99  0.039*
Hematocrit, % 35.1  04 35.6  0.6
Plasma [renin], 105GU/ml 13.2  3.6 16.0  2.6
Values are means  SE. Shown is the effect of lithium treatment at postnal
(P) days 7–28 on rat pup growth, kidney size, and plasma parameters.
Parentheses indicate concentration. *P  0.001, significantly different from
corresponding control group.
Fig. 1. Effect of lithium treatment for postnatal (P) days 7–28 on rat kidney
morphology. A and D: photos show macroscopic view of kidneys sectioned
along the longitudinal axis. Lithium treatment affected kidney architecture
with expanded pelvic space and occasional microcysts in the cortex-outer
medulla junction. B, C, E, and F: periodic acid-Schiff (PAS)-stained sections
from control and lithium-treated kidneys at P28. Lithium-treated kidneys
exhibit normal-appearing PAS-positive proximal convoluted tubules. Dilata-
tions and occasional microcysts were associated with PAS-negative tubules
found within all regions of the cortex and medullary junction (asterisks in E
and F). Based on confluency these tubules comprised cortical collecting ducts.
G: effect of lithium treatment on kidney region dimensions as quantified by
stereology at P28. Both cortex and outer medulla (OM), i.e., outer stripe (OS)
and inner stripe (IS) of outer medulla (OSOM and ISOM, respectively)
volumes were reduced while inner medulla (IM) was not affected. Values are
means SE. *P 0.05, ***P 0.001 compared with control; n 10 control
and n  14 lithium-treated animals.
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Case 2. Female, age 79, treated with lithium for 40 yr (kidney from
autopsy). Pathological description mentions “atrofic and fibrotic kid-
ney with cystic changes, lithium-induced.”
Case 3. Male, age 68 (kidney biopsy). Pathologist mentions “cor-
tical cysts (lithium-induced).” Duration of treatment not available
(“several years”).
Stereology
Stereology was performed according to Madsen et al. (18), Skyum
et al. (34), and Nyengaard (24). In short, kidneys were sliced in
1-mm-thick slices, and every second slice was stained with periodic
acid-Schiff (PAS). Stereological quantification of the different kidney
zones was performed using a light microscope with a motorized stage
table connected to a video camera and a computer using Cast 2000
software (Olympus). Volume fractions (Vv) of the different kidney
zones were determined by point counting at 	2 magnification in a
3 	 4-point grid. Total volume (V) of kidney zones was determined
as V(zone)  Vv times weight of kidney, assuming that the density of
kidney tissue is 1 mm3/mg.
Osmolality and Electrolyte Measurements
Osmolytes were extracted from inner medullary tissue samples as
previously described (37). Plasma, urine, and inner medullary inter-
stitial osmolality was determined by freeze-point depression (Osmo-
mat 030-D, Gonotec, Bie and Berntsen and Advanced Osmometer
3D3, Advanced Instruments). Na and K concentrations were de-
termined by flame photometry (model IL 943, Instrumentation Lab-
oratory, Lexington, MA). Inner medullary urea concentration was
determined as previously described (37). Plasma lithium concentra-
tion was determined by atomic absorption spectrometry (PerkinElmer
2380).
Messenger RNA Assays
Microdissection and isolation of RNA from rat pups at P16, 17, and
18 were done as previously described (18). cDNA was obtained by
reverse transcription of 1 g total RNA using an iScript cDNA
synthesis kit (Bio-Rad). PCR was performed as previously described
(37). Primer sequences were aquaporin-2 (AQP2) sense: 5=-tgg-gaa-
Fig. 2. Developmental postnatal regulation of
glycogen synthase kinase (GSK)-3 expres-
sion in rat kidney. A and B: Western blotting
experiments for total GSK-3 protein in kid-
ney homogenates obtained from a develop-
mental series of rat kidney cortices and me-
dullas. The expression of GSK-3 in cortex
decreased at weaning (P21) compared with
day of birth (P0). There was no change in the
expression of total GSK-3 protein in the
medulla between birth and postweaning
(P28). Values are means  SE; n  5–6.
***P  0.001. Simple blue staining con-
firmed equal protein loading (not shown).
C and D: Western blotting experiments for
serine-9 phosphorylated (inactive) GSK-3
(pGSK-3-s9) protein abundance in a devel-
opmental series of rat kidney cortex and me-
dulla homogenates. The expression of pGSK-
3-s9 decreased significantly in the first post-
natal week (P7) compared with birth and
through postweaning stages (P28) in both the
kidney cortex and medulla. Values are means 
SE. **P  0.01, ***P  0.001; n  5–6.
Simple slue staining confirmed equal protein
loading (not shown). E–J: in the rat kidney,
GSK-3-immunoreactive signal was ob-
served in collecting ducts, connecting tubules,
intraglomerular cells, and in loops of Henle
(E–H). Serial sections show that GSK-3 la-
beling was colocalized with aquaporin-2
(AQP2) in both cortical (G–I) and medullary
collecting ducts (H–J). Scale bar 50 m. In
each group, 4 kidney samples in total were
examined. K: PCR analysis of microdissected
cortical and outer medullary collecting ducts
from rats (P16–P18). Top: expression of
AQP2 mRNA that served as a positive control
for collecting ducts. Bottom: presence of
GSK-3 mRNA in the collecting ducts. In all
analyses, omission of reverse transcriptase
(RT) and addition of water instead of cDNA
served as negative controls. Size marker is

X174 DNA/HaeIII fragments.
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ctc-aga-tcc-ata-3= and antisense: 5=-cac-gga-ttt-cta-ctg-gag-3=; and
GSK-3 sense: 5=-caa-act-acc-aaa-tgg-gcg-3= and antisense: 5=-agt-
atc-tga-ggc-tgc-tgt-3=.
Western Blotting
Western blotting was performed as previously described (37).
Primary antibodies used were GSK-3 (9315, 1:2,500, Cell Signal-
ing), pGSK-3-s9 (9336, 1:1,000, Cell Signaling), PCNA (sc-7907,
1:2,000, Santa Cruz Biotechnology), -smooth muscle actin (SMA;
ab5694, 1:1,000, Abcam), E-cadherin (610181, 1:20,000, BD Biosci-
ences), and AQP2 (sc-9882, 1:1,000, Santa Cruz Biotechnology). The
antigen-antibody complex was visualized by horseradish peroxidase-
conjugated secondary antibodies (P0447, P0448 and P0449, all
1:2,000, Dako).
GSK-3 Kinase Activity
GSK-3 activity was determined in the kidney cortex from rats
treated with lithium (P7–P28) using a GSK-3 activity assay kit
(CS0990, Sigma). Protein homogenates were prepared as described
for Western blotting. Kinase activity was determined according to the
manufacturer’s guidelines. In short, GSK-3 was precipitated by incu-
bating 200 g of protein with Protein G Affinity Gel Beads and
anti-GSK-3 antibody for 3 h at 4°C. The immunoprecipitated kinase
was then incubated with substrate in the presence of -[32P]ATP. The
32P incorporated into the substrate was then measured.
Immunohistochemistry
Tissue sections were deparaffinized and rehydrated as described
previously (36). Antigen retrieval was carried out by boiling for 20
min. in either TEG buffer [10 mM Tris, 0.3 mM EGTA, pH 9.0
(Pharmacy, SDU)], 1	 Target Retrieval Solution (Dako), or 1	
Target Retrieval Solution Citrate buffer (Dako). Primary antibodies
used were GSK-3 (human: ab31366, 1:100, Abcam; rat: 9315,
1:100, Cell Signaling); pGSK-3 (human: 9336, 1:100, Cell Signal-
ing; rat: 9323, 1:100, Cell Signaling); AQP2 (sc-9882, 1:50, Santa
Cruz Biotechnology); E-cadherin (610181, 1:1,000, BD Biosciences);
and PCNA (sc-7907, 1:100, Santa Cruz Biotechnology). The antigen-
antibody complex was visualized by horseradish peroxidase-conju-
gated secondary antibodies (EnVision ready-to-use polymer, K4003,
and P04491: 100–1:1,000, both from Dako). For staining of apoptosis
with a terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) reaction, an In Situ Cell Death Detection Kit
was used according to the manufacturer’s description (Roche).
Statistics
All values are presented as means  SE. Two groups were
compared by unpaired Student’s t-test. Multiple comparisons were
analyzed with one-way ANOVA followed by Bonferroni’s multiple
comparison test. P  0.05 (*) was considered significant. P  0.01
and P  0.001 were designated ** and ***, respectively. All statis-
tical tests were performed using GraphPad Prism 5.01.
RESULTS
Effect of Postnatal Lithium Administration on Rat Kidney
Morphology
Rats subjected to lithium from P7 to P28 displayed signif-
icant growth retardation, while kidney/body weight ratio did
not differ (Table 1). Plasma lithium concentration was  1
mmol/l in lithium-treated rat offspring and not different from
zero in control rats (Table 1). Plasma Na concentration,
osmolality, hematocrit, and renin concentration were not dif-
ferent between groups (Table 1). The macroscopic appearance
of transected rat kidneys exposed to lithium from P7 to P28
showed a normal papilla but an expanded pelvic space and
occasional microcysts in the corticomedullary junction (Fig. 1,
A and D). Perfusion-fixed PAS-stained sections from lithium-
treated animals showed dilated distal tubules and cortical
collecting ducts and, in a few cases, cortical microcysts that
appeared to emanate from connecting tubules or collecting
ducts in medullary rays (Fig. 1, E and F). The inner medulla
showed no overt pathological changes. Stereological quantifi-
cation of regions from kidneys of rats exposed to lithium from
P7 to P28 showed that the volumes of cortex and outer medulla
but not inner medulla were reduced after lithium treatment
(Fig. 1G).
Fig. 3. Localization of total GSK-3 and pGSK-3-s9 in human fetal and adult kidney. A and B: immunohistochemical labeling of fetal human kidney sections
with an antibody specific for GSK-3. Especially in the medulla, signals were associated with collecting ducts (B). E and F: immunohistochemical staining of
adult human kidney sections for total GSK-3 showed signals from cells associated with parietal epithelial cells in glomeruli, cortical thick ascending limb of
Henle’s loop, distal convoluted and connecting tubules and along the whole collecting duct system. C, D, G, and H: labeling with an antibody specific for
pGSK-3-s9 yielded signals from the same structures as when labeled for total GSK-3 in both fetal and adult human kidney. Labeling of adult human kidney
was faint. Scale bar 50 m. In each group, 4 kidney samples in total were examined. Omission of primary antibody was used as a negative control (not shown).
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Developmental Changes in GSK-3 Protein Level
Western blotting experiments for GSK-3 showed a signif-
icantly lower abundance of total GSK-3 in the renal cortex at
P21 and P28 compared with P0 while levels remained constant
in the medulla with development (Fig. 2, A and B).Western
blotting experiments for pGSK-3-s9 showed a significantly
reduced abundance of phosphorylated protein in the cortex and
medulla at P7 that was maintained through P28 to a level
10–20% of that observed at P0 (Fig. 2, C and D). At P14 and
P29, a GSK-3-immunoreactive signal was observed in col-
lecting ducts, connecting tubules, in intraglomerular cells, and
in loops of Henle (Fig. 2, E–H). Labeling for AQP2 in
consecutive sections confirmed signals for GSK-3 to be
associated with principal cells in collecting ducts (Fig. 2, G vs.
I, H vs. J, and see also Fig. 5). GSK-3 was uniformly
associated with AQP2-positive cortical collecting ducts and
thus also found in intercalated cells (Fig. 2, G–J, and see also
Fig. 5I). Microdissected rat nephron segments displayed ex-
pression of GSK-3 and AQP2 mRNA in collecting ducts at
P16–P18, and products were detected only in the presence of
cDNA and of reverse transcriptase in the reaction (Fig. 2K).
Immunohistochemical Mapping of GSK-3 in Human Fetal
and Adult Kidney
GSK-3-immunoreactive protein was observed primarily in
collecting duct epithelium in the human fetal kidney at gesta-
tional week 29 while labeling of the cortex was faint. No
signals were associated with the nephrogenic zone, proximal
tubules, or glomeruli (Fig. 3, A and B). The adult human kidney
was immunopositive in the glomerular parietal epithelium,
intraglomerular cells, cortical thick ascending limb of Henle’s
loop (based on distinct labeling of the macula densa), and
along the whole collecting duct system (Fig. 3, E and F). There
was no obvious heterogeneity along the cells lining the med-
ullary collecting ducts in GSK-3-immunoreactive signal.
Phospho-GSK-3-s9 was found in the same structures in fetal
and adult human kidney as total GSK-3 (Fig. 3, C, D, G, and H).
Effect of Lithium Treatment on GSK-3 Level in Postnatal
Kidney
Lithium treatment from P7 to P28 did not change total
GSK-3 protein abundance in the cortex or medulla at P28 as
determined by Western blotting (Fig. 4, A and B). The immu-
nohistochemical signal for GSK-3 protein was not different
from the control seen in Fig. 2, G and H (not shown). In
contrast, pGSK-3-s9 protein abundance was significantly in-
creased by lithium treatment in the cortex and medulla as
confirmed by Western blotting (Fig. 4, C and D). The activity
assay for GSK- showed a tendency toward higher activity in
cortex from controls compared with lithium-treated animals
(366.3  5.9 and 209.6  93.7 counts/min for n  3 and n 
5, respectively). Immunohistochemical staining of lithium-
treated rat kidney sections at P28 for pGSK-3-s9 showed a
marked increase in staining intensity in subsets of cells partic-
ularly along the connecting tubule and cortical collecting duct
(Fig. 4G, serial sections identified the immunopositive nephron
segments Fig. 5, I–L). Immunopositive staining was compara-
tively weaker in the inner medulla (Fig. 4H). Cortex and
medulla from control kidneys were faintly labeled for pGSK-
3-s9 (Fig. 4, E and F).
Effect of P7–P28 Lithium Treatment on Cell Proliferation
and Epithelial Differentiation Markers
Protein abundance of the mitosis marker PCNA was signif-
icantly increased by lithium in both the cortex and medulla at
Fig. 4. Effect of lithium treatment from P7 to P28 on pGSK-3-s9 in rat
kidney. A and B: Western blotting experiments for total GSK-3 protein
abundance in cortex (A) and medulla (B) with and without lithium treatment.
There is no significant difference between the 2 experimental groups. Equal
protein loading was confirmed by simple blue staining (not shown). C and
D: Western blotting experiments for pGSK-3-s9 in cortex (C) and medulla
(D) with and without lithium treatment. The abundance of pGSK-3-s9 was
significantly increased after lithium treatment in both regions. Values are
means  SE. **P  0.01, ***P  0.001; n  8 for control and n  12 for
lithium-treated animals. Equal protein loading was confirmed by simple blue
staining (not shown). E and F: immunohistochemical staining of control
kidneys for pGSK-3-s9 showed faint signals associated with collecting ducts
and glomeruli in cortex (E), while immunopositive signals were virtually
absent from control medulla tissue (F). G and H: immunohistochemical
staining of sections from lithium-treated kidneys for pGSK-3-s9 showed a
marked signal associated with subsets of cells particularly along the cortical
connecting tubule and cortical collecting duct (G), while the effect of lithium
in the medulla was less obvious (H). Scale bar  50 m. In each group, 4
kidney samples in total were examined. Omission of primary antibody was
used as a negative control (not shown).
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P28 (Fig. 5, A and B). In control kidneys, PCNA was observed
dispersed over the cortical labyrinth with a larger density
toward the corticomedullary junction and in medullary rays
(Fig. 5G). Here, PCNA immunoreactivity was observed in
several nuclei in adjacent cells in loops of Henle and collecting
ducts. Typically, PCNA immunoreactivity displayed a decreas-
ing abundance along the corticomedullary axis and was virtu-
ally absent from the base of the inner medulla to the tip of the
papilla (not shown). In response to lithium, PCNA-positive
cells were more numerous and clearly observed in the cortico-
medullary junction (Fig. 5H). After lithium treatment, PCNA-
immunoreactive cells extended into the inner medulla (not
shown). The PCNA immunosignal colocalized with AQP2-and
GSK-3-positive and -dilated cortical collecting duct segments
but was not restricted to these segments (Fig. 5, I, K, and L).
PCNA-positive cells were not observed in GSK-3-positive
and Na-K-2Cl cotransporter (NKCC2)-positive cortical
thick ascending limbs of loops of Henle (Fig. 5, I–K).
The mesenchymal cell marker -SMA showed increased
abundance in the cortex and medulla after lithium treatment
from P7 to P28 (Fig. 5, C and D), while the epithelial cell
marker E-cadherin showed no significant difference (Fig. 5, E
and F). Immunohistochemical signal for E-cadherin was prom-
inent in collecting ducts with no change in intensity or distri-
bution between control and lithium (not shown). Detection of
apoptosis with TUNEL reaction by an In Situ Cell Death
Detection Kit at P28 showed this to be a very rare event at the
histological level with no obvious differences between control
and lithium treatment (not shown).
Effect of P7–P28 Lithium Treatment on Kidney Morphology
and Urine Concentrating Ability in Adult Rats
After discontinuation of lithium for 6 wk from P28, male,
but not female rats had a lower body weight while total kidney
weight was not significantly lower (Table 2). Kidney weight
expressed as a body weight ratio was not different in adult rats
that received lithium in the developmental period (Table 2).
Food and water intake in adult rats was not different between
treatment regimens or genders (Table 2). At baseline, urine
flow and urine osmolality in adult rats were similar between
controls and rats with postnatal lithium treatment (Table 2).
Kidneys displayed changes in the corticomedullary junction,
which was poorly defined, and in some cases microcysts were
present (Fig. 6, A and C). Perfusion-fixed PAS-stained sections
from lithium-treated adult rats showed slight changes, with
dilated tubules and occasional microcysts (Fig. 6D). Stereo-
logical quantification showed differential effects in male and
Fig. 5. Effect of lithium treatment from P7 to
P28 on epithelial differentiation markers. A
and B: Western blotting experiments for the
mitosis marker proliferating cell nuclear anti-
gen (PCNA) in cortex (A) and medulla (B)
from rats with and without lithium treatment
at P28. The abundance of PCNA protein is
significantly increased with lithium treatment.
C and D: Western blotting experiments for the
mesenchymal cell marker -smooth muscle
actin (-SMA) in cortex (C) and medulla (D)
with and without lithium treatment at P28.
The abundance of -SMA protein is signifi-
cantly increased with lithium treatment. E and
F: Western blotting experiments for the epi-
thelial cell marker E-cadherin in cortex and
medulla homogenates from kidneys with and
without lithium treatment at P28. There is no
significant difference between the 2 experi-
mental groups. Values are means  SE; n 
8 for control and n  12 for lithium-treated
animals. *P  0.05, **P  0.01. Equal pro-
tein loading was confirmed by simple blue
staining (not shown). G and H: immunohisto-
chemical labeling of rat kidney for PCNA.
Labeling was associated with epithelial cell
nuclei in medullary rays in control kidney
particularly at the corticomedullary junction
(G), and lithium treatment led to a discernible
increase in the number of positive epithelial
cells in this region (H). I–L: serial sections of
rat kidney at P28 stained for GSK-3 (I),
Na-K-2Cl cotransporter (NKCC2; J),
PCNA (K), and AQP2 (L). Arrows point to the
same structures in all 4 micrographs. AQP2-
positive collecting ducts were also positive for
GSK-3 (L vs. I). GSK-3-positive epithe-
lium included AQP2-negative structures of
which some were positive for NKCC2 (I vs. J
vs. L). Dilated microcystic tubules were
GSK-3 and AQP2 positive (I and L) and
PCNA positive (K). Scale bar  50 m.
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female rats: In male rats, cortical and inner medullary volumes
were not significantly different between control and early
lithium treatment, while outer medullary volume was signifi-
cantly reduced (Fig. 6E). Kidneys from lithium-treated female
rats displayed a reduced cortical volume while medullary
volumes were not altered (Fig. 6F). After lithium discontinu-
ation for 6 wk, plasma osmolality rose significantly more in
female rats treated from P7 to P28 with lithium (male rats P 
0.17) compared with control after water deprivation and
dDAVP bolus injection, while plasma Na concentration and
hematocrit were not different (Table 2). Adult male rats treated
postnatally with lithium displayed a significantly greater
weight loss after water deprivation (Table 2). After water
deprivation and dDAVP injection, urine flow was larger and
maximal urine osmolality was lower in male rats that had
received lithium early in life (Fig. 7, A and B), while these
parameters did not reach the significance limit in female
lithium-treated rats (P  0.27 and P  0.06) (Fig. 7, D and E).
Both adult female and male rats with postnatal lithium treat-
ment exhibited an attenuated ability to increase urine osmola-
lity ( osmolality) after water deprivation and dDAVP (Fig. 7,
C and F). In adult male rats treated postnatally with lithium, the
increase in osmolality by water deprivation and dDAVP was
significantly lower compared with female rats (Fig. 7, C and
F). Medullary interstitial fluid osmolality and concentration of
urea and electrolytes were not different between control and
lithium-treated male rats (Table 2). The protein abundance of
AQP2 as determined by Western blotting did not differ be-
tween lithium-treated and control rats (Table 2), and immuno-
histochemical labeling for AQP2 showed no difference (not
shown).
Effect of Chronic Lithium Treatment on Tissue Structure and
GSK-3 in Human Kidney
Sections of extirpated kidneys and a biopsy from patients
treated with lithium for several years displayed multiple, di-
lated tubules and microcysts that appeared to be oriented
longitudinally along the corticomedullary axis (Fig. 8, A and
E). Microcysts and tubular dilatations were located predomi-
nantly in the cortex and to a minor degree in cortical-outer
medullary junction and outer medulla (Fig. 8A), but not in the
inner medulla (Fig. 8B). Microcysts/dilatations were lined by a
single-layered low-cuboidal epithelium (Fig. 8, C and D). At
several sites, there was an abrupt transition from a tubule with
normal dimensions to a cyst (Fig. 8, C and D). Focal interstitial
fibrosis was seen in the kidney, especially in cortical areas with
tubular atrophy. In general, the glomeruli appeared normal.
Such alterations were not observed in age- and gender-matched
nephrectomy samples removed because of renal clear cell
carcinoma (Fig. 3). Immunolabeling for GSK-3 and pGSK-3
showed that signals were strongly and uniformly associated
with the cyst epithelium (Fig. 8, C–F). Adjacent cortical tissue
with normal appearance showed distinct immunopositive sig-
nals for GSK-3 associated with Bowman’s capsule, the con-
necting tubule and the collecting duct (Fig. 8E), similar to
control tissue (Fig. 3). The medulla displayed GSK-3 signal
associated with the collecting duct (Fig. 8B). Of note, the
microcysts, tubular dilatations, and GSK-3- and pGSK-3-
labeling pattern were similar in a necropsy kidney sample from
a chronic lithium user (Fig. 8, I and J) and a kidney biopsy
from a chronic lithium user (Fig. 8, M and N). Microcystic
epithelium was AQP2 negative in nephrectomy and necropsy
kidney (Fig. 8, G and K) while adjacent collecting ducts
exhibited labeling associated with the luminal surface. In the
kidney biopsy, microcystic epithelium showed apical labeling
for AQP2 (Fig. 8O). Mitotic cells were enriched in both cyst
epithelium but also in tubules, appearing normal as confirmed
with PCNA immunolabeling (Fig. 8, H, L, and P).
DISCUSSION
The present study shows by stereology and metabolic cage
experiments that administration of lithium to rats through
P7–P28 leads to somatic growth impairment that is permanent
in male rats, and to discrete structural injury of the kidney
Table 2. Effect of lithium treatment on in vivo parameters at P72
Males Females
Control (n  6) Lithium (n  8) Control (n  6) Lithium (n  8)
Basal condition
Body weight, g 347  7.9 324  6.9* 220  3.0 213  3.9
Total kidney weight, mg 2115  77 2077  68 1532  57 1444  32
Kidney weight/body weight ratio, mg/g 6.51  0.10 6.90  0.15 7.68  0.21 7.47  0.15
Water intake, ml  100 g1  24 h1 10.19  0.22 10.07  0.39 12.60  1.61 13.05  1.11
Urine flow, ml  100 g1  24 h1 5.22  0.28 4.83  0.33 6.79  1.11 7.14  0.74
Diet intake, g  100 g1  24 h1 7.28  0.18 7.66  0.13 7.75  0.55 8.41  0.22
Water deprivation for 30 h and dDAVP
Weight loss, % 8.02  0.18 8.85  0.24* 10.13  0.61 9.51  0.42
Plasma osmolality, mosmol/kgH2O 316.5  2.22 320.1  1.14 315.7  1.05 320.8  1.69*
Plasma [Na], mM 142.2  0.30 141.6  0.52 140.7  0.15 141.3  0.38
Plasma [K], mM 5.2  0.1 4.8  0.1* 5.2  0.2 4.9  0.1
Hematocrit, % 48.8  0.7 48.7  0.6 44.7  0.8 46.3  0.6
Papillary osmolality, mosmol/kgH2O 1359  115.1 1293  84.51
Papillary [urea], mM 477.7  78.3 424.9  55.8
Papillary [Na], mM 212.3  17.1 210.0  11.3
Papillary [K], mM 68.0  3.1 69.2  3.0
AQP2/-actin protein ratio (cortex) 1.19  0.03 1.23  0.07 1.19  0.11 1.29  0.10
AQP2/-actin protein ratio (medulla) 1.08  0.08 1.19  0.06 1.21  0.05 1.36  0.08
Values are means  SE. AQP2, aquaporin-2. Shown is the effect of lithium treatment (P7–P28) on rat growth, baseline parameters in metabolic cages, and
plasma and papillary parameters. *P  0.05, significantly different from corresponding control group.
F461LITHIUM AND POSTNATAL KIDNEY INJURY
AJP-Renal Physiol • doi:10.1152/ajprenal.00144.2011 • www.ajprenal.org
 by 10.220.33.2 on January 16, 2017
http://ajprenal.physiology.org/
D
ow
nloaded from
 
cortex-outer medulla, and attenuated maximal urine concen-
trating capacity in adult life. In control rats, the abundance of
pGSK-3-s9 decreased markedly in kidneys in the first post-
natal week. Lithium treatment through P7–P28 counteracted
the decrease in pGSK-3-s9 in subsets of collecting duct cells
associated with sites of pathological tissue changes. Develop-
ing and adult human kidney showed GSK-3 expression in the
collecting duct. Adult human kidneys from chronic lithium-
treated patients displayed multiple cortical microcysts immu-
nopositive for both GSK-3 and pGSK-3. The data are
compatible with a developmental increase in GSK-3 activity
(dephosphorylation) in the first postnatal weeks that is im-
paired by entry of lithium into cells in developing distal
nephron-early collecting duct epithelium. This event may be
essential to the observed dysregulated cell proliferation asso-
ciated with dilatations and microcysts and subsequent struc-
tural changes. The postnatal period appears to constitute a
window where the cellular uptake of lithium is favored in the
distal nephron similar to sodium-depleted states in adult ani-
mals (39) and where an accelerated microcystic phenotype
similar to chronic lithium use in humans can be induced. The
present dietary protocol results in therapeutic relevant concen-
trations of lithium in offspring plasma (10), and localization of
renal injury is compatible with observations in rat (28), mouse
(42), and human kidneys (13). No differences were recorded
between lithium-treated rats and controls at P28 in plasma
sodium, osmolality, hematocrit, and plasma renin concentra-
tion, which shows that access to extra NaCl prevented major
extracellular volume derangement. Postnatal polyuria per se by
e.g., disrupted of NKCC2, affects primarily the inner medulla-
papilla (38), which was not affected by the present protocol. In
adult lithium-treated rats, prevention of polyuria did not impair
tissue lesions (26). Therefore, lithium-induced polyuria is a
less likely explanation for the observed microcystic alterations.
Discontinuation of lithium for6 wk did not resolve the tissue
injury. Both genders showed injury, but only male rats showed
impaired somatic growth and a decrease in maximal urine
concentrating ability in adult life, which indicates a larger
susceptibility in males. In previous studies with continuous
lithium for 8 postnatal wk followed by discontinuation for 8
wk, only male rats were used and exhibited markedly reduced
GFR and urine concentrating ability (28). The current model
shows less severe changes but defines a narrow 3-wk window
of sensitivity to lithium that corresponds to the postnatal period
of avid sodium retention and maturation of the medulla (14,
21). In rats, lithium treatment from birth for either 8 or 16 wk
leads to a significant amount of atubular glomeruli, which
indicates loss of tubular epithelium (19). The present data
showed unchanged levels of AQP2 and E-cadherin protein in
adult rats that received lithium postnatally, which indicate no
major loss of tubular epithelial cells and principal cells. In
agreement, lithium-induced AQP2 downregulation is almost
normalized 3 wk after discontinued lithium in rat (2). The most
likely explanation for the permanent urine concentration defect
in adult rats is the structural component of the injury, with a
shorter cortical-papillary axis. Increased abundance of inactive
pGSK-3-s9 after lithium was associated predominantly with
subsets of cells in the distal nephron and collecting duct in both
human and rat kidney. In homogenates of total kidney cortex,
there was a nonsignificant tendency toward decreased GSK-3
activity after lithium treatment. This observation is in agree-
ment with the highly localized labeling pattern for pGSK-3
after lithium compared with the widespread total GSK-3
expression. A likely interpretation for the restricted distribution
of pGSK-3 to cortical collecting duct is that lithium reached
sufficiently high intracellular concentrations only in these cells
Fig. 6. Effect of lithium treatment from P7 to P28 on kidney morphology in
adult rat. A and C: macroscopic appearance of kidneys divided in the frontal
plane. Kidneys were from control and lithium-treated rats (P7–P28) and
harvested more than 6 wk after lithium discontinuation (P70–P72). Lithium-
treated kidneys showed changes in the corticomedullary junction. B and
D: PAS-stained kidney sections from control and lithium-treated (P7–P28)
kidney at P72. Lithium-treated kidneys showed slight changes with dilated
tubules and occasional microcysts. E: stereological quantification of male
kidney regional volumes showed that OSOM and ISOM were significantly
reduced. F: stereological quantification of female kidney regional volumes
showed that total kidney and cortex volume were significantly reduced. Values
are means  SE; n  14 control and n  16 lithium-treated animals. *P 
0.05, **P  0.01 compared with control.
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since the Ki of lithium for inhibition of GSK-3 is rather high,
on the order of 2 mmol/l (15). Several other observations
support that lithium causes alterations particularly in this seg-
ment of the nephron (8–10, 20, 27, 28). Amiloride, an epithe-
lial Na channel (ENaC) inhibitor, prevents inactivating phos-
phorylation of GSK-3 in adult short-term lithium-treated rats
(16). Disruption of ENaC prevents lithium-induced polyuria in
mice (7). This documents that ENaC is the apical entry path-
way for lithium and provides the cellular basis for the partic-
ular sensitivity to lithium of the aldosterone-sensitive parts of
the renal tubule (33). The present data show a distribution of
immunoreactive GSK-3 protein in developing and adult hu-
man kidney similar to the rat kidney (32, 41). Cystic lesions in
human kidneys after long-term lithium treatment were local-
ized predominantly in the cortex and the cortical-outer medul-
lary junction which has been reported by others in human
biopsies (1, 13). Microcysts were observed by magnetic reso-
nance imaging in 16 of 16 examined patients on lithium (12).
We show that the microcystic epithelium is continuous with
normally appearing tubules, exhibits proliferations, and is
GSK-3- and pGSK-3 immunopositive while largely AQP2
negative. In a human renal biopsy, the microcyst epithelium
was AQP2 positive, which indicates that collecting ducts can
be the origin of the microcysts. It can be concluded that there
is segmental colocalization of tubule dilatation/microcysts,
proliferating epithelium, and inactivating phosphorylation of
GSK-3 after lithium treatment in both rat and human renal
epithelium. Because these findings were similar in the human
autopsy kidney, in a whole-nephrectomy sample, and an
acutely fixed biopsy from three different individuals, the ob-
servations are less likely to be due to the ischemia, extracor-
poreal tissue handling, delayed fixation, etc. These observa-
tions suggest that the postnatal rat kidney is a rapid and valid
model for lithium-induced human kidney injury.
Germline collecting duct-specific knockout of GSK-3
yields a phenotype with increased diuresis, but no major tissue
Fig. 7. Effect of lithium treatment from P7 to P28 on urine concentration in adult rats. A: urine flow after water deprivation and dDAVP injection was significantly
higher for adult male animals treated with lithium for P7–P28 compared with controls. B: urine osmolality for adult male animals treated with lithium for P7–P28
and controls. At the basal level there was no difference between control and lithium-treated animals, but upon water deprivation and dDAVP injection both
lithium-treated and control animals showed increased urine osmolality. Lithium-treated animals attained a significantly lower urine osmolality compared with
controls. C: difference in osmolality between baseline and water deprivation/dDAVP administration was significantly lower in adult male rats treated with lithium
from P7 to P28 compared with controls. The increase in osmolality in lithium-treated male rats was significantly lower than in female rats (#). D: urine flow
after water deprivation and dDAVP injection was not different between control and adult female animals treated with lithium from P7 to P28. E: urine osmolality
in adult female animals treated with lithium from P7 to P28 and controls. At baseline, there was no difference between lithium and controls. Upon water
deprivation and dDAVP injection, both control and lithium-treated females had significantly increased urine osmolality. F: difference in osmolality between
baseline and water deprivation in adult female rats treated with lithium from P7 to P28 was significantly lower compared with control animals. Values are means 
SE; n  6 control and n  8 lithium-treated animals for both males and females. *P  0.05, **P  0.01, ***P  0.001 compared with control. #P  0.05 males
compared with females.
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alterations (31). There are several potential explanations: the
distal tubule-connecting tubule with less active AQP2 pro-
moter activity may have intact GSK-3 activity in this condi-
tional model, or there might be redundant function of intact
GSK-3 activity (17). pGSK-3 protein abundance was 10%
at weaning compared with the day of birth with similar total
protein abundance, which indicates that postnatal kidney dif-
ferentiation is associated with an increase in GSK-3 activity
in the medulla, similar to the developing rat brain (17).
GSK-3 activity prevents or limits epithelial proliferation, and
its inhibition may lead to the observed increase in PCNA (6).
However, other kinases upstream of GSK-3 or even GSK-3
might contribute to the observed increase in mitosis (22).
Stereological quantitation has shown hyperplasia of the cortical
connecting tubule-cortical collecting duct by lithium (37). It is
an intriguing possibility that the tubular dilatation/microcysts
in the rat kidney are caused by dysregulated cell proliferation.
In summary, we have established a rat model of lithium
treatment during postnatal kidney development that leads to
permanent functional and structural kidney injury and causes
microcysts, cell proliferation, and inactivation of GSK-3 by
phosphorylation in the distal nephron-collecting duct epithe-
lium. These alterations mimicked histological injury observed
in human kidney tissue from patients chronically treated with
lithium (PCNA-, GSK-3-, and pGSK-3-positive microcystic
epithelium). We conclude that the postnatal premature rat
kidney and the adult human kidney are susceptible to lithium
that enters cells of the aldosterone-sensitive distal nephron and
causes permanent tissue injury by signaling events that could
involve inhibition of GSK.
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Fig. 8. Morphology of human kidney sections from patients treated with lithium for several years. All sections were counterstained with hematoxylin and eosin.
A–H: nephrectomy kidney (lithium for 28 yr). I–L: autopsy kidney (lithium for 40 yr). M–P: biopsy from human kidney (chronic lithium user, period not
known). A and B: At low magnification, multiple microcysts were visible in cortex (A) but not in medulla (B). C–E, L, and M: immunolabeling showed GSK-3
associated with epithelial cells in dilated tubules (C), microcysts (D and arrow in E), and normally appearing tubules (E). Microcysts were continuous with tubules
that appeared normal (C and D). F, J, and N: immunohistochemical staining for pGSK-3-s9 shows signals associated with epithelium in dilated tubules and
microcysts (arrow in F). G, K, and O: immunostaining for AQP2 in nephrectomy and autopsy kidney (G and K) showed signal associated with collecting duct,
but no obvious association with microcyst epithelium. In biopsy material, cyst epithelium showed apical labeling for AQP2 (O). H, L, and P: immunostaining
for PCNA was associated with epithelial cells predominantly in dilated tubules and in microcysts (arrows) and occasionally in tubules appearing normal. Scale
bars: 500 m (A and B), 200 m (E–G and K), and 50 m (C and D, H–J, and L–P).
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